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http://dxObjective: The current Surgical Care Improvement Project (SCIP) measure for controlled postoperative 6-AM
glycemic control after cardiac surgery identifies those with blood glucose levels of200 mg/dL. The purpose of
the present study was to evaluate the effect of achieving this SCIP measure on risk-adjusted postoperative car-
diac surgical outcomes.
Methods: The data were analyzed for all cardiac surgery patients from a single institution (June 2010 to August
2012). The patients were categorized by the postoperative 6-AM glucose levels into 2 SCIP measure cohorts:
SCIP (200 mg/dL) versus non-SCIP (>200 mg/dL). Propensity-matched cohort comparisons and multiple
regression analyses assessed the associations between SCIP measure compliance and the risk-adjusted out-
comes.
Results: Of 1703 patients, 1527 (90%) achieved SCIP measure glycemic control. Preoperative diabetes was
more common among the non-SCIP patients (P<.001); the median Society of Thoracic Surgeons-predicted
mortality (P ¼ .14) was similar between the 2 groups. No significant differences were observed in major
morbidity, mortality, or resource usage among the propensity-matched cohorts. After adjustment for Society
of Thoracic Surgeons-predicted risk, non-SCIP status was not associated with increased mortality (P ¼ .44),
composite major morbidity (P ¼ .16), major sternal complications (P ¼ .68), total intensive care unit duration
(P ¼ .70), or postoperative length of stay (P ¼ .27). Similar risk-adjusted results were estimated for patients
undergoing isolated coronary artery bypass grafting.
Conclusions: Achieving the SCIP measure for controlled postoperative 6-AM blood glucose levels200 mg/dL
after cardiac surgery was not associated with improved risk-adjusted mortality, morbidity, or hospital resource
usage. These data suggest that this metric might not be a valid measure of postoperative cardiac surgical quality.
(J Thorac Cardiovasc Surg 2014;147:1041-8)P
MHyperglycemia is ubiquitous among critically ill patients
and in the postoperative setting after cardiac surgery.1
Multifactorial in nature, postoperative hyperglycemia re-
sults from the concomitant effects of stress-induced release
of cytokines and the influence of cardiopulmonary bypass,
dextrose-containing fluids, corticosteroids, and the gluco-
genic effects of epinephrine and other catecholamines.2-5
Historically, the treatment of hyperglycemia <200
mg/dL in the postoperative setting was not considered thee Virginia Interdisciplinary CardioThoracic Outcomes Research (VICTOR)
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More recently, however, studies of critically ill patient pop-
ulations have demonstrated a negative association between
stress-induced hyperglycemia and poor outcomes.5-13 One
noteworthy study of cardiac surgical patients
demonstrated an increased association between sternal
wound complications and elevated blood glucose (BG)
levels.14 In response to that study, the Surgical Care
Improvement Project (SCIP) developed a quality perfor-
mance measure to maintain the 6-AM controlled blood
glucose levels at <200 mg/dL on postoperative days
(PODs) 1 and 2.15 Although select single-institutional retro-
spective series have evaluated the current SCIP measure,
most reports have focused on evaluating whether the
SCIP measure is a good proxy for postoperative glycemic
control, and a few have reported on unadjusted outcomes
data.16 Thus, additional investigation to more firmly estab-
lish the appropriateness of the current SCIP measure within
risk-adjusted cardiac surgical patient populations is needed.
The purpose of the present study was to evaluate the
effect of achieving the SCIP measure for controlled BG
on risk-adjusted postoperative cardiac surgical outcomes.diovascular Surgery c Volume 147, Number 3 1041
Abbreviations and Acronyms
BG ¼ blood glucose
CABG ¼ coronary artery bypass grafting
ICU ¼ intensive care unit
POD ¼ postoperative day
SCIP ¼ Surgical Care Improvement Project
STS ¼ Society of Thoracic Surgeons
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MWe tested the null hypothesis that the postoperative out-
comes would not be significantly different after cardiac sur-
gery as a function of SCIP measure failure.METHODS
Patients
The University of Virginia institutional review board approved the pre-
sent study, including an institutional waiver for the need to obtain patient
consent. The data from all patients undergoing cardiac surgery at the Uni-
versity of Virginia were entered prospectively into a certified institutional
Society of Thoracic Surgeons (STS) Adult Cardiac Surgery database. We
retrospectively reviewed all adult (age>18 years) patients undergoing car-
diac operations from June 2010 to August 2012. During the study period,
our institution prospectively gathered the 6:00-AM BG levels on PODs 1
and 2, with the specific intention of evaluating our performance with the
currently established SCIP measure. The patient records were stratified
into 2 primary study cohorts according to the achievement of the SCIP
measure: SCIP (6-AM BG 200 mg/dL) versus non-SCIP (6-AM BG
>200 mg/dL).
The patient demographics, preoperative risk factors, operative fea-
tures, and postoperative outcomes were compared between the 2 study
groups. Consistent with the current SCIP measure guideline definitions,
the POD 1 and 2 6:00-AM BG values were the single serum values
obtained on each postoperative morning at or near (but before) 6:00 AM.
The established STS definitions were used for all preoperative variables,
postoperative complications, and outcomes.17 All patient outcomes of in-
terest were established a priori before data collection. Operative mortality
was defined as patient deaths occurring before hospital discharge or
within 30 days postoperatively. The composite incidence of major
morbidity was defined by the incidence of permanent stroke, periopera-
tive myocardial infarction, prolonged mechanical ventilation (>24
hours), pneumonia, and renal failure. Major sternal complications
included the composite incidence of deep sternal wound infection, sternal
dehiscence, and mediastinitis.
Statistical Analysis
The primary outcomes of interest were differences in the propensity-
matched and risk-adjusted outcomes as a function of SCIP measure failure.
The secondary outcomes of interest included differences within the entire
study cohort with respect to the unadjusted incidence of postoperative
morbidity, mortality, and resource usage between the SCIP measure
groups. All study group comparisons were unpaired. Categorical variables
were compared using either Pearson’s c2 or Fisher’s exact test, and contin-
uous variables were compared using Student’s t test for normally distrib-
uted data or the Wilcoxon rank sum test for non-normally distributed
data, as appropriate.
To account for the potential confounding effects between the study co-
horts on the postoperative outcomes, propensity score matching was per-
formed to generate a study cohort of matched SCIP and non-SCIP
patients. The propensity scores were estimated using logistic regression
modeling, with the failure to achieve the SCIP measure (non-SCIP status)1042 The Journal of Thoracic and Cardiovascular Suras the response variable and patient age, gender, operative status (elective,
urgent, emergency), procedure type, and reoperation (vs primary opera-
tion) status as the possible confounding predictor variables. The propen-
sity scores were then used to match the SCIP and non-SCIP patients in a
1:1 ratio using the nearest neighbor greedy method, resulting in equal-
size study cohorts. The postoperative outcomes were then compared be-
tween the matched groups using standard univariate statistical tests of
association.
To further account for potential confounding in the patient risk profiles
and to verify the results observed in the propensity-matched cohorts, multi-
variate regression models were used to estimate the risk-adjusted associa-
tions between the predictor variable of interest (non-SCIP status) and the
likelihood of several different response variables: mortality, major
morbidity, major sternal complication, total intensive care unit (ICU) dura-
tion, and postoperative length of stay. All model response variables were
selected a priori, and the estimated associations between non-SCIP status
and outcomes were adjusted for the patient risk profiles using the estab-
lished calculated STS predictive indexes, Predicted Risk of Mortality and
Predicted Risk of Mortality or Morbidity, as the other modeled factors. Lo-
gistic regression model discrimination between each response variable and
the predictor variables was assessed using model c-statistics. The amount
of variance in the response variable explained by the model was assessed
using Nagelkerke pseudo-R2 values, and the Hosmer-Lemeshow test was
used to assess model calibration across the deciles of observed and pre-
dicted risk.
All categorical variables are expressed as a percentage of the group of
origin, and continuous variables are expressed as either the mean  stan-
dard deviation or median and interquartile range. Odds ratios with the
95% confidence intervals are used to report the results of the multivariable
logistic regression analyses, and predictor variable coefficients with a stan-
dard error are reported for multivariate linear regression analyses. All re-
ported P values are 2-tailed. Data analysis was performed using R
statistical software, version 2.12.1 (The R Foundation for Statistical
Computing, available at: http://www.R-project.org).RESULTS
Comparison of Patient Characteristics and Risk
Factors
A total of 1703 patients underwent cardiac operations at
the University of Virginia during the study period. Achieve-
ment of the SCIP measure occurred in 1576 patients
(89.6%) and SCIP measure failure occurred in 176
(10.4%). The patient demographics, preoperative charac-
teristics, and operative features as a function of SCIP mea-
sure status are listed in Table 1.
The average patient age was similar between the 2 study
cohorts. Overall, men were more commonly represented in
both study groups. Non-SCIP patients presented with a
greater prevalence of preoperative diabetes, dyslipidemia,
peripheral arterial disease, previous percutaneous inter-
vention and coronary artery bypass grafting (CABG).
Non-SCIP patients also presented with a greater burden
of coronary artery disease (3-vessel disease, 46% vs
34%, P<.001). Non-SCIP patients more frequently un-
derwent isolated CABG (CABG-only) surgery, and SCIP
patients more often underwent valve procedures with or
without concomitant operations. Despite these differ-
ences, the differences in preoperative risk as defined by
the calculated median STS Predicted Risk of Mortalitygery c March 2014
TABLE 1. Descriptive statistics for patient risk factors between SCIP
and non-SCIP patients
Factor
SCIP
(n ¼ 1527)
Non-SCIP
(n ¼ 176)
P
value
Patient age (y) 65.1  14.7 65.1  13.2 .66
Gender .98
Female 34.8 34.7
Male 65.2 65.3
Cerebrovascular disease 18.2 19.9 .59
Diabetes 30.3 69.3 <.001
Dyslipidemia 73.5 83.0 .006
Hypertension 76.9 76.7 .93
Infective endocarditis 4.5 1.7 .11
Peripheral arterial disease 17.0 25.0 .01
Renal failure 3.5 4.5 .52
Previous CABG 9.2 14.8 .02
Previous PCI 17.8 25.6 .02
Previous valve surgery 8.2 5.7 .3
Atrial fibrillation 19.4 17.6 .62
Previous MI 35.3 40.9 .16
Diseased coronary arteries (n) <.001
1 11.4 6.8
2 16.2 19.3
3 33.7 45.5
Aortic insufficiency
(moderate to severe)
11.5 5.7 .08
Mitral insufficiency
(moderate to severe)
23.0 19.9 .34
Aortic stenosis 32.3 26.7 .04
Mitral stenosis 4.1 6.2 .09
Ejection fraction (%) 57 (43-63) 57 (34-63) .08
STS PROM score (%) 2.0 (0.8-4.9) 2.3 (1.0-5.3) .14
STS PROMM score (%) 16.6 (9.9-28.7) 18.2 (12.3-32.4) .04
Procedure type <.001
CABG only 29.4 39.2
AV replacement 18.3 13.6
MV repair 3.8 4.0
MV replacement 3.1 2.8
AV replacement plus CABG 7.7 6.2
MV repair plus CABG 2.2 2.8
MV replacement plus CABG 0.9 1.1
AV plus MV replacement 0.6 0.6
Other 34.1 29.5
Operative status .99
Elective 61.2 61.4
Urgent 36.0 35.8
Emergency 2.8 2.8
Data presented as mean  standard deviation, %, or median (interquartile range).
SCIP, Surgical Care Improvement Project; CABG, coronary artery bypass grafting;
PCI, percutaneous coronary intervention; MI, myocardial infarction; STS, Society
of Thoracic Surgeons; PROM, Predicted Risk of Mortality; PROMM, Predicted
Risk of Mortality or Morbidity; AV, atrioventricular; MV, mitral valve.
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Mwas not significantly different between the 2 groups (SCIP,
2.0% vs non-SCIP, 2.3%; P ¼ .14). Most cardiac opera-
tions were performed in the elective setting within both
study cohorts; approximately 40% were performed in
the urgent or emergency setting.The Journal of Thoracic and CarComparison of Unadjusted Postoperative Outcomes
as Function of Achieving SCIP Measure
The distribution of postoperative BG levels on POD 1
(Figure 1, A) and POD 2 (Figure 1, B) for all patients.
The median PODs 1 and 2 BG level for the non-SCIP pa-
tients was 223 and 224 mg/dL and was 135 and 141
mg/dL for the SCIP patients, respectively (P< .001 for
both; Figure 2). Select differences in the incidence of post-
operative complications and events were also observed be-
tween the unadjusted SCIP measure study groups. No
significant differences in either perioperative cardiovascu-
lar or mechanical and infection-related sternal complica-
tions were observed between the 2 groups. Postoperative
hospital resource usage was also similar. However, the un-
adjusted incidence of prolonged mechanical ventilation
(21.6% vs 10.9%, P<.001) and renal failure (11.4% vs
5.9%, P ¼ .009) was greater among the non-SCIP patients.
Thus, non-SCIP patients demonstrated a greater unadjusted
composite incidence of major morbidity (21.0% vs 12.6%,
P ¼ .003) and operative morality (9.5% vs 3.5%,
P ¼ .002).Adjusted Effect of Achieving SCIP Measure on
Postoperative Outcomes (Propensity-Matched
Cohort)
In an effort to reduce the influence of bias and confound-
ing in the reported results, the patient outcomes among the
SCIP and non-SCIP groups were compared between the
propensity-matched cohorts (Table 2). Overall, after pro-
pensity matching, the incidence of postoperative events
and major morbidity, including deep sternal wound infec-
tion and major sternal complications, was not significantly
different between the matched SCIP and non-SCIP patient
populations. Furthermore, the operative mortality rates
and median total ICU and postoperative length of stay
were not different when stratified by SCIP measure adher-
ence or failure.Effect of SCIP Measure Failure on Risk-Adjusted
Outcomes
To further verify the adjusted results obtained between
the propensity-matched patient cohorts, the risk-adjusted
effect of SCIP measure failure (non-SCIP status) on the
likelihood of mortality, composite major morbidity, major
sternal complications, and hospital resource usage was as-
sessed within the entire study cohort (n¼ 1703) and a sub-
group of patients undergoing CABG-only surgery
(n ¼ 518) using regression modeling (Table 3). Multivar-
iate regression analyses demonstrated that after adjust-
ment for patient risk profile, using either the calculated
Predicted Risk of Mortality (in the mortality model) or
the Predicted Risk of Mortality or Morbidity (morbidity
and resource usage models) as covariates in the model,diovascular Surgery c Volume 147, Number 3 1043
FIGURE 1. Histograms displaying distribution of (A) postoperative day 1
and (B) postoperative day 2 6:00-AM blood glucose levels for all patients
undergoing cardiac operations (n ¼ 1703). FIGURE 2. Box plots for (A) postoperative day 1 and (B) postoperative
day 2 6:00-AM blood glucose levels for Surgical Care Improvement Project
(SCIP) versus non-Surgical Care Improvement Project (NSCIP) study co-
horts (n ¼ 1703).
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MSCIPmeasure failure was not associated with the probabil-
ity of death (P ¼ .44), the composite incidence of major
morbidity (P ¼ .16), major sternal complications
(P ¼ .68), a prolonged ICU duration (P ¼ .69), or an
increased postoperative length of stay (P ¼ .27). More-
over, similar results were obtained for the CABG-only
cohort. Each statistical model achieved adequate discrim-
ination, with c-statistics ranging from 0.72 to 0.78, and
described 10% to 18% of the variance existing in each
response variable (ie, Nagelkerke pseudo-R2 ¼ 0.10-
0.18). Model calibration for all logistic regression models
was acceptable, with Hosmer-Lemeshow P>.05.DISCUSSION
The present study has reported on the effect of the estab-
lished SCIP quality performance measure for postoperative1044 The Journal of Thoracic and Cardiovascular Surcontrolled BG among cardiac surgery patients. Our findings
from a total study cohort of 1703 patients undergoing car-
diac surgery at a single institution, suggest that achievement
of the SCIP measure of controlled 6-AM BG on PODs 1 and
2 does not improve the patient outcomes in both propensity-
matched cohort analyses and mortality and morbidity risk-
adjustment models. Furthermore, a lack of association
between SCIPmeasure failure and patient outcomes was es-
tablished within a subset of patients undergoing isolated
CABG. Overall, these results have expanded previous
investigative efforts that have challenged this quality mea-
sure for postoperative cardiac surgical care, and they have
extended the investigation into larger patient samples with
a report on the risk-adjusted outcomes.gery c March 2014
TABLE 2. Comparison of postoperative complications and events
within propensity-matched cohorts of SCIP versus non-SCIP patients
Postoperative complication
or event
SCIP
(n ¼ 176)
Non-SCIP
(n ¼ 176)
P
value
POD 1 BG (mg/dL) 138 (120-156) 223 (207-243)<.001
POD 2 BG (mg/dL) 131 (117-149) 224 (210-259)<.001
Perioperative myocardial infarction 0.0 0.6 >.99
Stroke 2.3 4.0 .54
Pneumonia 4.5 5.7 .81
Prolonged ventilation 15.9 21.6 .22
Renal failure 9.7 11.4 .73
Deep sternal wound
infection/mediastinitis
0.0 0.6 >.99
Major sternal complication 0.0 0.6 >.99
Composite major morbidity 17.6 21 .5
Operative mortality 6.2 9.1 .42
Total ICU length of stay (h) 52 (21-98) 64 (23-116) .61
Postoperative length of stay (d) 6 (4-9) 6 (5-9) .08
Data presented as median (interquartile range) or%. SCIP, Surgical Care Improve-
ment Project; POD, postoperative day; BG, blood glucose; ICU, intensive care unit.
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MSubstantial research has been conducted during the past
few decades to determine the effect of postoperative hyper-
glycemia after cardiac surgery and, perhaps more impor-
tantly, to provide clinical direction regarding the best
practices to improve patient outcomes. The available pub-
lished data represent prospective and retrospective levels
of evidence in both diabetic and nondiabetic patient popula-
tions, many with significant methodologic issues related to
potential confounding and bias. Thus, mixed results have
been reported, and the debate regarding the most efficacious
strategy for postoperative BG management for cardiac sur-
gery patient populations remains unsettled.
Accumulated evidence has supported the potential bene-
ficial effects of tight glycemic control after cardiac sur-
gery.1,18-22 Perhaps most important was a report from
Ingels and colleagues23 of 970 high-risk cardiac surgery pa-
tients that demonstrated a long-term survival benefit for
those with tight glycemic control (goal BG, 80-110
mg/dL) compared with those with goal BG targets of 180
to 200 mg/dL. Furnary and colleagues18 demonstrated a
similar mortality benefit among 3500 CABG patients withTABLE 3. Risk-adjusted associations between SCIPmeasure failure (non-S
those undergoing CABG-only surgery (n ¼ 518)
Outcome
All patients
Estimate* (95% CI or SE)
Mortalityy 1.49 (0.54-4.09)
Major morbidityz 1.51 (0.86-2.67)
Major sternal complicationz 1.58 (0.18-13.7)
Total ICU LOS (h)z 6.93 (17.8)
Postoperative LOS (d)z 0.64 (0.58)
SCIP, Surgical Care Improvement Project; CABG, coronary artery bypass grafting; CI, co
*Adjusted odds ratio or regression coefficient with corresponding 95% CI. yzEach mode
of ySTS PROM (P<.001 for both models) or zSTS PROMM (P<.01 for both models) a
The Journal of Thoracic and Cardiabetes in a report that established the ‘‘Portland Protocol’’
for continuous postoperative intravenous insulin infusion.
The same group subsequently reported on a series of an
additional 2000 patients in which they advocated the use
of a 3-day average of all BGmeasurements (3-BG) obtained
from the day of surgery through the second POD to assess
perioperative glycemic control.19 They demonstrated that
patients with 3-BG values>200 mg/dL had significantly
greater in-hospital mortality, deep sternal wound infection,
and hospital length of stay.19 In a more recent report by Gia-
koumidakis and colleagues,21 however, no significant dif-
ferences in the postoperative ventilation rates, infectious
complications, or ICU and hospital length of stay were de-
tected between patients with a target BG of 120 to 160
mg/dL and those with a target BG of 161 to 200 mg/dL dur-
ing the first 24 hours postoperatively. Moreover, multiple
studies have associated poor glycemic control with sternal
wound infections in diabetic patients after cardiac sur-
gery,14,20,24 resulting in the development of the current
SCIP measure for postoperative morning controlled BG.
The currently established SCIP measure for postopera-
tive controlled BG after cardiac surgery has been the focus
of increasing debate within the present and other investiga-
tions.16,25 In a recent report by McDonnell and
colleagues,16 the validity of the current SCIP measure as a
proxy for postoperative glycemic control was investigated
in a cohort of 832 patients (both diabetics and nondiabetics)
undergoing CABG, valve (repair or replacement), and
CABG plus valve operations. By demonstrating a lack of
association between SCIP measure compliance and unad-
justed patient outcomes, the investigators suggested that
the SCIPmeasure BG values do not legitimately proxy post-
operative glycemic control.16 In contrast, a report by Mur-
phy and colleagues25 examined compliance with the SCIP
6:00-AM BG measurement among 110 consecutive cardiac
surgery patients and concluded that the measurement was
a valid surrogate for overall glycemic control but that the
use of an insulin infusion protocol did not guarantee overall
glycemic control. The incidence of SCIP noncompliance in
their series was 9% (n ¼ 10). Thus, the results of these 2
series complement those from the present series andCIP status) and primary study outcomes for all patients (n¼ 1703) and
CABG only
P value Estimate* (95% CI or SE) P value
.44 1.79 (0.44-7.32) .42
.16 1.08 (0.41-2.83) .88
.68 — —
.69 14.8 (16.7) .38
.27 0.1 (0.68) .99
nfidence interval; SE, standard error; ICU, intensive care unit; LOS, length of stay.
l was adjusted for the influence of baseline patient operative risk through inclusion
s other modeled factors with the regression models.
diovascular Surgery c Volume 147, Number 3 1045
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Mprovide a foundation for the added analyses of our report.
The most significant limitations of these 2 former series
concern the heterogeneity and/or small sample sizes in their
analyses and a lack of adjustment for potential confounding
and bias in their results. Therefore, the results of the present
study have addressed these limitations in a larger patient
population and have extended the analyses to control for po-
tential confounding using propensity-matched cohort com-
parisons and risk-adjustment regression modeling. In the
present series, the rate of SCIP measure failure (10%)
was similar to those observed in the former series, and the
failure of an association between SCIP measure compliance
and adjusted mortality, morbidity, and resource usage was
recapitulated. Perhaps most significant was the lack of rela-
tionship between major sternal wound complications,
including deep sternal wound infections and mediastinitis,
and SCIP measure compliance in both unadjusted and
adjusted analyses. These results support those of the previ-
ously published series by McDonnell and colleagues16 and
other investigators that have demonstrated a lack of an asso-
ciation between SCIP measure compliance and the postop-
erative infection rates.26-28
In the present analyses, the outcomes related to SCIP
measure compliance were also evaluated for a subgroup
of patients undergoing isolated CABG, because many other
series that investigated the management of postoperative
hyperglycemia have restricted their analyses to CABG pa-
tients alone.18,19,22,29-31 In this subgroup of patients, SCIP
measure failure also did not have a significant association
with patient outcomes and resource usage after
adjustment for preoperative risk using the established, and
widely accepted, calculated STS predictive risk indexes.
These results further strengthened the argument for re-
evaluation of the currently accepted SCIP measure, because
CABG patients typically represent a cohort of patients with
the lowest overall operative risk profiles.
The results of the present study have important clinical
and patient quality-based implications, and they highlight
important limitations of the current SCIP measure. Of fore-
most importance is the implication that the currently estab-
lished SCIP measure should not be used as a valid measure
of postoperative cardiac surgical quality. Second, the pre-
sent results argue that the currently measured SCIP
threshold value for serum BG (200 mg/dL) does not appear
to adequately correlate with postoperative infection rates,
other measure of morbidity, or mortality. This observation
is not surprising, because most of the cited published series
have investigated much narrower glycemic control ranges
and suggested that patient outcomes could be improved
with lower, more moderate glucose levels. Thus, the pre-
ponderance of evidence from our study and elsewhere sug-
gests that an inherent limitation of the current SCIPmeasure
is the failure to identify those for whom improved outcomes
and surgical quality might be achieved. One possible1046 The Journal of Thoracic and Cardiovascular Surexplanation for this observation is that the current threshold
of 200 mg/dL used by the SCIP measure is too high and that
the category of patients with BG<200 mg/dL includes
many patients who experience poor outcomes owing to rela-
tively uncontrolled hyperglycemia (eg, BG of 180-200
mg/dL). Thus, the outcomes for this patient cohort might
have been ‘‘inflated’’ and biased the results of the compar-
isons between the SCIP compliant and noncompliant
groups, just as in the present study, toward the null. An addi-
tional limitation of the SCIP measure concerns the methods
required to measure and report glycemic control. As re-
ported in other series, measurement of a single BG level,
instead of alternative measurements (eg, average glucose
levels, 3-BG), might over- or underestimate the relation-
ships between glycemic control and outcomes. These find-
ings, therefore, add to the existing debate and call for a
definitive, multi-institutional randomized clinical trial to
help direct surgeons and quality assessment groups
regarding the appropriate clinical standards and guidelines.
In the current surgical era with an increasingly complex and
higher risk patient population, emphasis on the establish-
ment of such surgeon-directed quality performance mea-
sures remains critical.
Consistent with existing published data, our institutional
practice has strongly favored aggressive postoperative
glucose control. Just as demonstrated in recent analyses,
the current SCIP guideline provides little guidance to sur-
geons, hospitals, quality performance bodies, or multidisci-
plinary care teams to assist in directing patient care and
improving patient outcomes. Despite this, however, sub-
stantial retrospective and prospective, randomized data
exist, supporting the beneficial effects of improved glyce-
mic control on postoperative cardiac surgical outcomes
and resource usage. Thus, in accordance with the latest
guidelines, our institution has striven for moderate glycemic
control in the perioperative setting for cardiac surgical pa-
tients, with the initiation of an established insulin infusion
protocol titrated to achieve a BG level<150 mg/dL (abso-
lutely<180 mg/dL) and to maintain hypoglycemia (BG 
70 mg/dL) rates of<1%. We have favored the initiation
of glycemic control in the operating room, the use of proto-
col compliance and direction measures such as computer-
based protocol decision programs, and frequent (ie, hourly)
point of care glucose testing in the initial postoperative
period until the glucose levels have stabilized. Strict mea-
sures within our protocol for the cessation of enteral and/
or parenteral glucose sources are critical to prevent serious
hypoglycemic events. We have favored alternative mea-
sures of glycemic control to those advocated by the existing
SCIP measure, including daily and 3-BG or median BG
measurements, in addition to tracking the percentage of
glucose measurement values outside the protocol’s target
range and glucose variability with protocol use. Finally,
we believe that a multidisciplinary quality assurance groupgery c March 2014
LaPar et al Perioperative Managementcharged with continuously evaluating patient compliance,
performance, and outcomes remains critical to advancing
protocol efforts designed to achieve improved postoperative
glycemic control.
The reported results had select limitations. First, inherent
selection bias should be considered in any retrospective re-
view. Second, the analyzed 6:00-AM BG values represented
single serum values obtained on the morning of PODs 1 and
2 and did not take into account the influence of BG vari-
ability occurring during the early postoperative period.
However, this limitation highlights a fundamental failure
of the existing SCIP measure. The reported results were
limited to a single institution experience and might not be
generalizable to other centers and clinical settings. In addi-
tion, the reported results were subject to the limitations of
the relatively small sample sizes in our propensity-
matched cohort comparisons and that our risk-adjusted
models explain 10% to 18% of the variance in the modeled
response variables. Thus, larger cohort analyses in the
future will add increased statistical power to the present re-
sults. Finally, these analyses were restricted to the short-
term outcomes and could not provide perspective on the
long-term outcomes or study endpoints. Nevertheless, the
strengths of using several methods to account for potential
cofounding and bias in our results have provided the largest
and most contemporary analysis of risk-adjusted outcomes
as a function of the current SCIP measure for cardiac surgi-
cal quality in the United States.P
MCONCLUSIONS
From the present results, achieving the SCIP measure for
controlled postoperative 6:00-AM BG levels of200 mg/dL
after cardiac surgery was not associated with improved risk-
adjusted mortality, morbidity, or ICU and postoperative
lengths of stay. These data suggest that this metric might
not be a valid measure of postoperative cardiac surgical
quality. Although the reported data did not support the cur-
rent use of glycemic control as measured according to the
SCIP guidelines to improve patient outcomes, our institu-
tion has strongly favored an insulin infusion-based,
protocol-driven approach to postoperative glycemic control
to achieve moderate target BG levels. Future prospective,
multi-institution clinical trials are needed to provide more
definitive clinical standards and guidelines for the manage-
ment of postoperative hyperglycemia after cardiac surgery.
Cardiac surgical quality standards should be determined
from the highest level of clinical evidence, and surgeon
involvement in the development of future quality metrics re-
mains critical.References
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